Form 4: DMII Director Shulgan Acquires 100,000 Shares

Myron W. Shulgan, a director of Drugs Made In America Acquisition II Corp., acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Summary

• Myron W. Shulgan, a director of Drugs Made In America Acquisition II Corp. (DMII), acquired 100,000 ordinary shares.
• The transaction occurred on September 26, 2025.
• The shares were acquired from Drugs Made In America Acquisition II LLC, the Issuer's sponsor.
• The acquisition was made for no consideration.
• Following this transaction, Myron W. Shulgan directly beneficially owns 100,000 ordinary shares.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even for no consideration, generally indicates alignment of interests with shareholders, which is a minor positive signal.

Positives

• A director increasing their beneficial ownership, even without direct cash outlay, generally signals alignment of interests with the company's future performance.
• The transaction strengthens the director's vested interest in the company's success.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or operations.

Industry Context

This transaction is typical for a Special Purpose Acquisition Company (SPAC) where initial equity stakes for directors and founders are often established through acquisitions from the sponsor, sometimes for nominal or no consideration, to align interests ahead of a potential business combination.

Comparison to Industry Standards

• The acquisition of shares by a director from a SPAC sponsor for no consideration is a common mechanism in the SPAC industry to establish initial equity ownership and align management incentives with shareholder interests. This practice is consistent with industry norms for SPAC formation and early-stage director compensation.

Related Party Transactions

• Myron W. Shulgan, a director, acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor. This constitutes a related party transaction as the sponsor is typically controlled by or closely affiliated with the company's management and directors.

Stakeholder Impact

• Shareholders: The transaction indicates increased alignment of a director's interests with the company's performance, which can be viewed positively.

Key Dates

Recommendation

The director's acquisition of shares, even without direct cash outlay, indicates a vested interest and alignment with the company's future. While a positive signal, this single transaction is not significant enough to warrant a strong buy or sell recommendation, suggesting a 'hold' for existing investors.

Keywords

Drugs Made In America Acquisition II Corp., DMII, Myron W. Shulgan, Form 4, Insider Transaction, Share Acquisition, Director Ownership, SPAC